Equity Overview
Price & Market Data
Price: $2.96
Daily Change: +$0.33 / 11.15%
Range: $2.69 - $2.99
Market Cap: $230,976,496
Volume: 2,022,152
Performance Metrics
1 Week: 12.98%
1 Month: 13.85%
3 Months: 24.89%
6 Months: 171.6%
1 Year: 157.4%
YTD: 57.45%
Company Details
Employees: 213
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.